Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence

Chen, Eric; Beutler, Sascha S.; Kaye, Alan D.; Edinoff, Amber N.; Khademi, Seyed-Hossein; Stoltz, Andrea E.; Rueb, Nicole R.; Cornett, Elyse M.; Suh, Winston

doi:10.5812/aapm.121402

Cited by 9 publications

(8 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both mirogabalin and cebranopadol seem to be potential novel treatment options for neuropathic pain. Although they have been found effective and well-tolerated in clinical trials in patients suffering from various types of chronic and acute postoperative pain [25][26][27][28][29][30][31][32][33][34][35][36][37][38], there is very limited data about their efficacy at the preclinical level, i.e., in some experimental models of pain resulting from drug-induced injuries to peripheral sensory nerves. For this reason, this in vivo research was focused on the assessment of the effects of mirogabalin and cebranopadol on the pain threshold in mice exposed to neuropathy-inducing drugs.…”

Section: Discussionmentioning

confidence: 99%

Naturally Inspired Molecules for Neuropathic Pain Inhibition—Effect of Mirogabalin and Cebranopadol on Mechanical and Thermal Nociceptive Threshold in Mice

Sałat,

Zaręba,

Awtoniuk

et al. 2023

Molecules

View full text Add to dashboard Cite

Background: Neuropathic pain is drug-resistant to available analgesics and therefore novel treatment options for this debilitating clinical condition are urgently needed. Recently, two drug candidates, namely mirogabalin and cebranopadol have become a subject of interest because of their potential utility as analgesics for chronic pain treatment. However, they have not been investigated thoroughly in some types of neuropathic pain, both in humans and experimental animals. Methods: This study used the von Frey test, the hot plate test and the two-plate thermal place preference test supported by image analysis and machine learning to assess the effect of intraperitoneal mirogabalin and subcutaneous cebranopadol on mechanical and thermal nociceptive threshold in mouse models of neuropathic pain induced by streptozotocin, paclitaxel and oxaliplatin. Results: Mirogabalin and cebranopadol effectively attenuated tactile allodynia in models of neuropathic pain induced by streptozotocin and paclitaxel. Cebranopadol was more effective than mirogabalin in this respect. Both drugs also elevated the heat nociceptive threshold in mice. In the oxaliplatin model, cebranopadol and mirogabalin reduced cold-exacerbated pain. Conclusions: Since mirogabalin and cebranopadol are effective in animal models of neuropathic pain, they seem to be promising novel therapies for various types of neuropathic pain in patients, in particular those who are resistant to available analgesics.

show abstract

Section: Discussionmentioning

confidence: 99%

Naturally Inspired Molecules for Neuropathic Pain Inhibition—Effect of Mirogabalin and Cebranopadol on Mechanical and Thermal Nociceptive Threshold in Mice

Sałat,

Zaręba,

Awtoniuk

et al. 2023

Molecules

View full text Add to dashboard Cite

show abstract

“…Mirogabalin is the current novel gabapentinoid being explored in the pain field. The drug shows promising results to treat pain conditions with good efficacy and tolerability [200].…”

Section: α2δ Subunit Blockadementioning

confidence: 99%

Current Drug Development Overview: Targeting Voltage-Gated Calcium Channels for the Treatment of Pain

Antunes

Campos

Carvalho³

et al. 2023

IJMS

View full text Add to dashboard Cite

Voltage-gated calcium channels (VGCCs) are targeted to treat pain conditions. Since the discovery of their relation to pain processing control, they are investigated to find new strategies for better pain control. This review provides an overview of naturally based and synthetic VGCC blockers, highlighting new evidence on the development of drugs focusing on the VGCC subtypes as well as mixed targets with pre-clinical and clinical analgesic effects.

show abstract

“…The results indicated that mirogabalin was effective in reducing pain and improving sleep quality. However, it is important to note that mirogabalin is primarily associated with the central nervous system (CNS) side effects, with somnolence, dizziness, and headache being the most commonly reported [ 27 ]. These side effects appear to increase in incidence with higher doses of mirogabalin, although their severity remains relatively constant.…”

Section: Reviewmentioning

confidence: 99%

Beyond the Pain: A Systematic Narrative Review of the Latest Advancements in Fibromyalgia Treatment

Ram,

Jeyaraman,

Jeyaraman

et al. 2023

Cureus

View full text Add to dashboard Cite

Fibromyalgia is a complex chronic pain disorder that significantly impacts the quality of life of affected individuals. The etiology of fibromyalgia remains elusive, necessitating effective treatment options. This review aims to provide an overview of current treatment options for fibromyalgia and highlight recent updates in managing the condition. The methodology employed in this systematic review comprised the following key steps. We conducted a comprehensive search across various databases to identify pertinent studies published between 2000 and 2023. Inclusion criteria were defined to specifically target studies involving adult individuals diagnosed with fibromyalgia, with a focus on both pharmacological and non-pharmacological interventions for managing the condition. The review encompassed a range of study types, including randomized controlled trials, observational studies, and systematic reviews. To ensure the quality of the selected studies, we employed appropriate assessment tools, and data extraction and synthesis adhered to established guidelines. This rigorous approach allowed for a robust analysis of the literature on fibromyalgia management. In the course of our review, it became evident that a spectrum of treatment approaches holds significant promise in the management of fibromyalgia. Specifically, pharmacological interventions, including selective serotonin-norepinephrine reuptake inhibitors, anticonvulsants, cannabinoids, tropisetron, and sodium oxybate, have exhibited substantial potential in alleviating fibromyalgia symptoms. Concurrently, non-pharmacological strategies, such as cognitive-behavioral therapy, exercise regimens, and complementary and alternative therapies, have yielded positive outcomes in improving the condition's management. Recent developments in the field have introduced innovative pharmacological agents like milnacipran and pregabalin, in addition to non-pharmacological interventions like mindfulness-based stress reduction and aquatic exercise, expanding the array of options available to enhance fibromyalgia care and alleviating patient symptoms. Fibromyalgia necessitates a multidisciplinary approach to treatment, encompassing both pharmacological and non-pharmacological interventions. Recent updates in fibromyalgia management offer additional options to alleviate symptoms and improve the quality of life for individuals with fibromyalgia. Healthcare professionals should remain informed about these advancements to provide evidence-based care, addressing the complex symptoms associated with fibromyalgia and enhancing patient outcomes.

show abstract

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence

Cited by 9 publications

References 50 publications

Naturally Inspired Molecules for Neuropathic Pain Inhibition—Effect of Mirogabalin and Cebranopadol on Mechanical and Thermal Nociceptive Threshold in Mice

Naturally Inspired Molecules for Neuropathic Pain Inhibition—Effect of Mirogabalin and Cebranopadol on Mechanical and Thermal Nociceptive Threshold in Mice

Current Drug Development Overview: Targeting Voltage-Gated Calcium Channels for the Treatment of Pain

Beyond the Pain: A Systematic Narrative Review of the Latest Advancements in Fibromyalgia Treatment

Contact Info

Product

Resources

About